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Background:  Patients  with cardiomyopathy  show  a signiﬁcantly  increased  risk  for  thromboembolic  events
due to  a  hypercoagulable  state  and platelet  dysfunction.  The  pathophysiologic  mechanism  underlying
the  increasing  platelet  activity  in patients  with  cardiomyopathy  remains  unclear.  We  performed  a  clinical
study to elucidate  the  link  between  myocardial  tissue  alterations  and  platelet  activation  in patients  with
cardiomyopathy.
Methods: A  total  of  30  patients  with  suspected  cardiomyopathy  and 10 healthy  control  patients  were
included  in  our study.  Hemodynamic  parameters  were  measured  by catheterization  and  echocardi-
ography.  Endomyocardial  biopsies  were  taken  to  determine  myocardial  inﬂammation.  Flow  cytometry
was  performed  to examine  the  platelet  activation  by  quantiﬁcation  of p-selectin  and  thrombospondin
expression  on  platelets.
Results:  The  p-selectin  (8.46  ±  3.67  AU)  and  thrombospondin  (26.56  ± 23.21  AU)  expression  was  signif-
icantly  correlated  with  the amount  of CD3+  T  cells  (p-selectin:  r = 0.573,  p  < 0.05;  thrombospondin:
r  =  0.488,  p  < 0.05)  and  the  endothelial/interstitial  activation  (p-selectin:  r = 0.521,  p  < 0.05;  throm-
bospondin:  r  = 0.39,  p  <  0.05).  This  was  found  to be independent  of  hemodynamic  parameters,  age,  and
gender.  The  platelet  activation  of  patients  (n =  3)  with  echocardiographically  documented  ventricular
thrombi  was  signiﬁcantly  increased  (p-selectin:  12.57  ± 5.5 AU  vs. 8.1  ± 3.2  AU, p < 0.05)  and  this  was
associated  with  elevated  myocardial  inﬂammation  scores.
Conclusion:  Myocardial  inﬂammation  is associated  with  a signiﬁcant  increase  in  platelet  activation  and
matio
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ntroduction
Non-ischemic cardiomyopathy (CM) is a serious disorder lead-
ng to high morbidity and mortality because of arrhythmic events
nd sudden death [1]. The myocardial disorder is characterized
y an impaired systolic or diastolic heart function combined with
hanges in ventricular diameters and pressures. These alterations
redispose to ventricular thrombus formation with increased risk
or stroke, peripheral arterial occlusion, and pulmonary embolism
2].
The etiology of CM includes various factors such as myocardial
iral infections, genetic variations, autoimmune disorders, or
oxic agents. After exclusion of a possible ischemic genesis for
mpaired cardiac function, CMs  are classiﬁed into 5 groups
ccording to their ventricular diameters, intra-ventricular
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pressures, and myocardial tissue alterations: dilated car-
diomyopathy (DCM), hypertrophic cardiomyopathy, restrictive
cardiomyopathy, arrhythmogenic right ventricular cardiomyopa-
thy, and unspeciﬁed cardiomyopathies (UCM) [3,4].
DCM is characterized by impaired contractile heart function
and ventricular chamber enlargement. One important causal fac-
tor for the development of DCM is the presence of a myocardial
viral infection, triggering inﬂammatory processes such as increased
inﬂammatory cytokine and chemokine expression as well as inﬁl-
tration of proinﬂammatory T cells and macrophages. A chronic state
of these inﬂammatory processes might result in myocardial alter-
ations as deﬁned by the existence of DCM.
Higher rates of ischemic strokes in patients with symptoms of
heart failure have already been demonstrated [5]. As described by
the “Virchow’ Triad” abnormal blood ﬂow, vessel wall abnormal-
ities, and pathologic changes in blood constituents may lead to
an increased risk of thrombogenesis [6]. Thus far, clinical studies
have failed to show a direct relation between only depressed
hemodynamic conditions and thromboembolic events, pointing
vier Ltd. All rights reserved.
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o additional pathophysiologic alterations that mediate blood
ypercoagulability in patients with CM.  Therefore, clear guidelines
bout the necessity of anticoagulant therapies in patients with
on-ischemic CM are still missing [7].
A pro-thrombotic state is at least in part characterized by
ncreased platelet activation [8–10]. Patients with CM have already
een reported to have signiﬁcant abnormalities in platelet function,
hat contribute to a hypercoagulable state [11]. Chronic cardiac
issue alterations including increased myocardial inﬂammation
nd vascular constriction have been suggested to contribute to
ndothelial and platelet dysfunction in cases of CM [12,13].
Thus our clinical study was performed to elucidate the link
etween myocardial alterations and platelet function. Therefore,
latelet activation was assessed by quantiﬁcation of activation-
ependent protein expression on the platelet surface in patients
ith suspected CM and correlated with markers of endothelial acti-
ation and myocardial inﬂammation.
ethods
tudy design
A total of 30 patients with suspected non-ischemic CM and
0 healthy control patients were included in our study, consid-
ring medical history, symptoms, physical examination, and
on-invasive test. The patients were enrolled into the study if they
ad both (1) clinically suspected CM by history and symptoms
dyspnea or exercise intolerance, angina, and palpitations) or by
istory and electrocardiographic changes (rhythm disturbances,
T-segment, or T-wave deviations) and (2) echocardiographic
ndings of left ventricular dysfunction (regional wall motion
bnormalities or global left ventricular dysfunction). The presence
f coronary artery disease was excluded in all patients with coro-
ary angiography. Left ventricular ejection fraction (LVEF) was
etermined by left ventricular catheterization and ventriculogra-
hy. Right ventricular catheterization was performed in all patients
o take endomyocardial biopsies from the right ventricular sep-
um with a standard bioptome. Patients with severe respiratory
nfections, tumor disease, renal insufﬁciency, hematological dis-
rders or other severe disease were excluded from the study.
urthermore, echocardiographic analysis was performed at the
ime of enrollment to assess left ventricular end-diastolic diameters
LVEDD), left atrium diameter, and to detect possible ventricu-
ar thrombus formation. Patients were classiﬁed into 4 groups
f non-ischemic CM according to their hemodynamic and car-
iac inﬂammatory characteristics: (1) DCM without inﬂammation
LVEF < 50%, LVEDD > 55 mm,  negative cardiac inﬂammation score);
2) DCM with inﬂammation (DCMi: LVEF < 50%, LVEDD > 55 mm,
ositive cardiac inﬂammation score); (3) CM with inﬂammation
CMi: LVEF ≥ 50%, LVEDD < 55 mm,  positive cardiac inﬂammation
core); (4) UCM (LVEF ≥ 50%, LVEDD < 55 mm,  negative cardiac
nﬂammation score, symptoms of heart failure or electrocardio-
raphic changes). A positive myocardial inﬂammation score was
eﬁned according to the Dallas criteria and criteria of the World
eart Federation (WHF) [14].
The study protocol was approved by the local ethics committee.
t was performed in accordance with the ethics principles in the
eclaration of Helsinki. Written informed consent was provided
y each patient before participation in the study.
mmunohistochemical assessment of myocardial biopsiesMyocardial biopsies were prepared and evaluated as previously
escribed. HLA-1, HLA-DR, and ICAM-1 were evaluated as mark-
rs for activation of endothelial and interstitial cells within theiology 63 (2014) 379–384
myocardial tissue. Expression of HLA-1, HLA-DR, and ICAM-1 on
endothelial and interstitial cells was  semiquantitatively scaled 0
(normal), 1 (intense), 2 (abundant), 3 (very abundant) according
to the intensity of immunoperoxidase staining of the cells [15].
The activation of the endothelial and interstitial cells was graded
according to the sum of HLA-1, HLA-DR, and ICAM-1 expression
on each cell type (minimum: 0; maximum: 18). Further cellular
inﬁltrates (CD3+ cells, CD45+ cells, and activated macrophages)
within the myocardial tissue were also assessed as a measure of
myocardial inﬂammation as previously described [16,17].
Measurement of in vivo platelet degranulation
Venous blood was  drawn from all patients into a platelet-
stabilizing agent containing 134 mmol  ethylenediaminetetraacetic
acid and 20 units heparin (ratio 9 volumes blood plus 1 volume
reagent). The blood was  immediately ﬁxed in 0.5% paraformalde-
hyde (pH 7.4). Platelet-rich plasma was  prepared for the
measurement of in vivo platelet degranulation as described before
[18]. The platelets were incubated with mouse IgG (unspeciﬁc bind-
ing) or a monoclonal antibody against p-selectin, thrombospondin,
or ﬁbrinogen (all antibodies from Coulter Immunotech, Marseille,
France), followed by a secondary ﬂuorescein isothiocyanate-
labeled antibody (SIGMA, St Louis, MO,  USA). Flow cytometry was
thereafter performed (FACScan, Becton Dickinson, San José, CA,
USA) as previously described [19–21].
Statistical analysis
SPSS statistical software version 16.0 (Chicago, IL, USA) was
used for all statistical analyses. Graphical illustrations were done
by SPSS statistical software version 16.0 and GraphPad Prism
Version 4.03 (San Diego, CA, USA). All data were expressed as the
mean ± standard deviation (SD), except for data in the ﬁgures that
are presented as the mean ± standard error of the mean (SEM). A
p-value < 0.05 was regarded as statistically signiﬁcant. Quantitative
variables with normal distribution were analyzed with Student’s
t-test, and variables without normal distribution with a two-tailed
Mann–Whitney U-test. The correlation analyses were performed
with Pearson’s and Spearman’s test. Bonferroni’s correction was
not performed. Multivariate linear regression was  calculated to
analyze the factors independently affecting speciﬁc variants. An ˛
error <5% was considered statistically signiﬁcant. Our multivariate
linear regression was  performed as a stepwise backward elimi-
nation process, deleting statistically non-signiﬁcant parameters
subsequently. Possible multicollinearity was  tested by determi-
nation of the variance inﬂation factor (VIF) and the tolerance of
each included parameter. A VIF >5 was regarded as a critical sign
of existing multicollinearity.
Results
Thirty patients with non-ischemic CM were included during
the study period. Patient characteristics are shown in Table 1,
demonstrating hemodynamic and myocardial inﬂammation pat-
terns of the study patients. A total of 7 patients were classiﬁed into
the DCM group, 7 patients into the DCMi group, 8 patients into
the CMi  group, and 8 patients into the UCM group. The platelet
activation was  evaluated by ﬂow cytometry and the expression
of p-selectin (8.46 ± 3.67 AU), thrombospondin (26.56 ± 23.21 AU),
and ﬁbrinogen (25.47 ± 8.62) on the platelet surface was  quantiﬁed
(Fig. 1). Compared to a healthy control group (n = 10), p-selectin
(5.8 ± 1.99 AU, p < 0.05), thrombospondin (12.8 ± 9.21 AU, p < 0.05),
and ﬁbrinogen (14.1 ± 3.55 AU, p < 0.05) expression were signiﬁ-
cantly increased in patients with non-ischemic CM.
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Table  1
Patient characteristics.
Study patients
n = 30
Sex (female/male) 5/25
Age (years) 48.2 ± 13
LVEF (%) 45.4 ± 17
LVEDD (mm) 62.7 ± 11
CD3+ T cells (n/mm2) 2.69 ± 2
CD45+ T cells (n/mm2) 1.29 ± 2
Interstitial activation 4.22 ± 1.3
Endothelial activation 4.27 ± 1.2
Hemoglobin (g/dL) 14.01 ± 0.6
Hematocrit (%) 41 ± 2.6
Leucocytes (n/nL) 7.3 ± 1.1
Platelets (n/nL) 319 ± 54.8
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tVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diam-
ter.
A reduced left ventricular ejection fraction did not lead to
igniﬁcantly different p-selectin, thrombospondin, and ﬁbrinogen
xpression patterns. In contrast, patients with increased endothe-
ial and interstitial activation had an increased p-selectin and
hrombospondin expression on platelets (Fig. 1).
As demonstrated in Figs. 2A and 3A, the platelet expression
f p-selectin as well as thrombospondin was signiﬁcantly corre-
ated with the activation of cardiac interstitial and endothelial cells
p-selectin: r = 0.521, p < 0.05; thrombospondin: r = 0.39, p < 0.05)
nd with myocardial inﬂammation as assessed by CD3+ T cells
ig. 1. Platelet activation demonstrated by p-selectin, thrombospondin, and ﬁbrinogen
ytometry. Results were expressed in scatter dot blots (top line). Patients were divided i
50%,  n = 16) and to the endothelial and interstitial activation (≤8, n = 15 vs. >8, n = 15) t
hese  groups (bottom line). Data are presented as mean ± SEM.iology 63 (2014) 379–384 381
(p-selectin: r = 0.573, p < 0.05; thrombospondin: r = 0.488, p < 0.05).
Moreover, activation of cardiac interstitial and endothelial cells
was correlated signiﬁcantly with the amount of myocardial CD3+ T
cells (r = 0.452, p < 0.05). A multivariate linear regression model was
performed to demonstrate the effect of myocardial inﬂammation
and endothelial/interstitial activation on the p-selectin and throm-
bospondin expression on platelets (Table 2). Various parameters
such as hemodynamic values (LVEF, LVEDD), cardiac inﬂammation
scores (CD3+ T cells, CD45+ T cells, interstitial/endothelial acti-
vation), and patient characteristics (age, gender) were included
in the model. After subsequent exclusion of non-signiﬁcant
variants the amount of CD3+ T cells and the myocardial inter-
stitial/endothelial activation were found as the only parameters
with appropriate impact on platelet activation (Table 2). Both
parameters accounted for ∼30% of the variation of p-selectin or
for ∼28% of the variation of thrombospondin expression in our
model.
Ventricular thrombus formation was documented by echo-
cardiography in three patients of the study population. All of
them showed a signiﬁcantly increased p-selectin platelet expres-
sion compared to patients without ventricular thrombus (Fig. 2B;
with thrombus: 12.57 ± 5.5 AU; without thrombus: 8.01 ± 3.2 AU,
p < 0.05). The thrombospondin expression on platelets in patients
with ventricular thrombus formation was  also increased in ten-
dency (Fig. 3B; with thrombus: 49.6 ± 25 AU; without thrombus:
24 ± 22, p = 0.069). As illustrated in Figs. 2A and 3A patients with
ventricular thrombus showed an above average elevated platelet
activation that was  associated with increased cardiac inﬂammation
and endothelial activation.
 expression. Expression of activation markers on platelets was assessed by ﬂow
nto 2 groups according to left ventricular ejection fraction (LVEF) (<50%, n = 14 vs.
o demonstrate p-selectin, thrombospondin, and ﬁbrinogen expression patterns in
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Fig. 2. P-selectin expression is associated with cardiac inﬂammation. (A) Correlations between p-selectin expression with endothelial/interstitial activation and CD3+ T
cells  are shown in scatter blots. Patients with thrombus formation were marked with black points. (B) P-selectin expression on platelets is demonstrated according to the
incidence of ventricular thrombus formation (yes: with thrombus, n = 3; no: without thrombus: n = 27). Data are presented as mean ± SEM.
Fig. 3. Thrombospondin expression is associated with cardiac inﬂammation. (A) Correlations between thrombospondin expression with endothelial/interstitial activation
and  CD3+ T cells are shown in scatter blots. Patients with thrombus formation were marked with black points. (B) Thrombospondin expression on platelets is demonstrated
according to the incidence of ventricular thrombus formation (yes: with thrombus, n = 3; no: without thrombus: n = 27). Data are presented as mean ± SEM.
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Table  2
Multivariate linear regression model for platelet activation markers. Linear regression was  calculated after inclusion of potential covariants. Non-signiﬁcant covariants such
as  left ventricular ejection fraction, left ventricular end-diastolic diameter, age, gender and CD45+ T cells were subsequently excluded, leaving the amount of CD3− T cells
and  endothelial/interstitial activation as contributors for the most efﬁcient model. The multiplicative term (correlation × standardized  × 100) explains the variation of
p-selectin or thrombospondin illustrated by the respective parameter in per cent.
Correlation Standardized  Correlation × standardized  × 100 p-Value
P-selectin
Endothelial/interstitial activation 0.359 0.33 11.8 0.056
CD3+  T Cells 0.443 0.424 18.8 0.016
Thrombospondin
Endothelial/interstitial activation 0.383 0.411 15.7 0.049
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iscussion
This study examined the association between myocardial
nﬂammation and platelet activation in patients with suspected
on-ischemic CM.  Positive correlations were demonstrated in
atients with CM between increased p-selectin and throm-
ospondin expression as markers of platelet activation and
yocardial inﬂammation.
Despite the well acknowledged hypercoagulability in patients
ith CMs  and reduced heart function, larger clinical trials failed to
emonstrate the beneﬁt of anticoagulant therapies in patients with
mpaired ejection fraction. The WARCEF and the WATCH trials did
ot ﬁnd any evidence to support the use of oral anticoagulant med-
cations in patients with CMs  and reduced LVEF [22,23], pointing to
he necessity to describe further characteristics that help to predict
he individual risk of thrombotic events [24,25]. These parameters
ight be useful to detect patients with CMs  independent of their
eft ventricular function who beneﬁt from an anticoagulant ther-
py. Current guidelines do not recommend in general the use of
ral anticoagulation in patients with DCM [26,27].
Patients with DCM present a systemic hypercoagulable state
ith increased circulating ﬁbrinogen and d-dimer blood levels
28,29]. Furthermore, increased systemic von Willebrand factor
xpression as well as elevated concentrations of ﬁbrinopeptide A
nd thrombin–antithrombin complexes are demonstrated in these
atients as indicators for a prothrombotic condition. The missing
ink between reduced ventricular function and the prothrombotic
tate in patients with CM supports our hypothesis of further char-
cteristics with procoagulant impact on the coagulation system.
herefore, we elucidated the association of myocardial inﬂamma-
ion with platelet activation.
Myocardial inﬂammation triggered by virus inﬁltration is asso-
iated with endothelial dysfunction that signiﬁcantly correlates
ith the expression of myocardial adhesion molecules [12]. Abnor-
alities of myocardial endothelial cell function lead to impaired
itric oxide synthesis with activating effects on platelets in patients
ith CMs  [30]. Moreover, endothelial cell damage associated with
levated expression of procoagulant factors such as thrombo-
odulin or soluble selectin have been observed in patients with
mpaired heart function [31]. Nevertheless, myocardial inﬂam-
ation seems to be associated with a hypercoagulable condition
hat leads to an increased risk for ventricular thrombus forma-
ion in cases of acute myocarditis [32]. The clinical observation
as supported by ﬁndings in different murine myocarditis mod-
ls that conﬁrmed the higher incidence of cardiac thrombus
ormation [33]. In a murine model acute viral myocarditis was
ssociated with increased myocardial tissue factor expression.
issue factor contributes to a hypercoagulative state and its expres-
ion in cardiac myocytes is anti-apoptotic under inﬂammatory
tress [34–36]. Therefore, we here described a direct relation
etween myocardial inﬂammation documented as increased CD3+
 cell inﬁltration and elevated interstitial/endothelial activation
[
[12.1 0.066
and platelet dysfunction. Thus, we  hypothesized that myocardial
inﬂammation, especially endothelial activation, would be asso-
ciated with increased platelet activation and an accompanying
increased risk for ventricular thrombus formation. This associa-
tion was  independent of hemodynamic values as well as age or
gender. Our data support the importance of assessing myocardial
inﬂammation to determine the thromboembolic risk of patients
with CMs.
In conclusion, we demonstrated for the ﬁrst time a signiﬁcant
impact of myocardial inﬂammation on platelet dysfunction inde-
pendently of the hemodynamic conditions in patients with CM.
Disclosures
None.
Acknowledgments
Peter Bobbert was  supported by “Friedrich C. Luft” Clinical
Scientist Pilot Program funded by Volkswagen Foundation and
Charité Foundation. The study was supported by grants from the
DFG-Sonderforschungsbereich SFB-TR19.
References
[1] Uretsky BF, Thygesen K, Armstrong PW,  Cleland JG, Horowitz JD, Massie BM,
Packer M,  Poole-Wilson PA, Ryden L. Acute coronary ﬁndings at autopsy in heart
failure patients with sudden death: results from the assessment of treatment
with lisinopril and survival (ATLAS) trial. Circulation 2000;102:611–6.
[2] Chesebro JH, Ezekowitz M,  Badimon L, Fuster V. Intracardiac thrombi and sys-
temic thromboembolism: detection, incidence, and treatment. Annu Rev Med
1985;36:579–605.
[3] Schultheiss HP, Noutsias M,  Kuhl U, Gross U, Lassner D, Poller W,  Pauschinger
M.  Cardiomyopathies II. Hypertrophic cardiomyopathy, restrictive cardiomy-
opathy, arrhythmogenic right ventricular cardiomyopathy. Internist (Berl)
2005;46:1373–85.
[4] Schultheiss HP, Noutsias M,  Kuhl U, Lassner D, Gross U, Poller W, Pauschinger
M.  Cardiomyopathies. I: classiﬁcation of cardiomyopathies-dilated cardiomy-
opathy. Internist (Berl) 2005;46:1245–56.
[5] Witt BJ, Brown Jr RD, Jacobsen SJ, Weston SA, Ballman KV, Meverden RA,
Roger VL. Ischemic stroke after heart failure: a community-based study. Am
Heart J 2006;152:102–9.
[6] Smadja DM,  Bura A, Szymezak J, Blanchard A, Remones V, Azizi M, Gaussem P.
Effect of clopidogrel on circulating biomarkers of angiogenesis and endothelial
activation. J Cardiol 2012;59:30–5.
[7] Lip GY, Piotrponikowski P, Andreotti F, Anker SD, Filippatos G,  Homma S,
Morais J, Pullicino P, Rasmussen LH, Marin F, Lane DA. Thromboembolism and
antithrombotic therapy for heart failure in sinus rhythm. An Executive Sum-
mary of a joint Consensus Document from the ESC Heart Failure Association and
the ESC Working Group on Thrombosis. Thromb Haemost 2012;108:1009–22.
[8] Chesebro JH, Rauch U, Fuster V, Badimon JJ. Pathogenesis of thrombosis in
coronary artery disease. Haemostasis 1997;27(Suppl. 1):12–8.
[9] Elsherbiny IA, Shoukry A, El Tahlawi MA.  Mean platelet volume and its relation
to  insulin resistance in non-diabetic patients with slow coronary ﬂow. J Cardiol
2012;59:176–81.
10] Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH. Thrombus for-
mation on atherosclerotic plaques: pathogenesis and clinical consequences.
Ann  Intern Med  2001;134:224–38.
11] Chung I, Lip GY. Platelets and heart failure. Eur Heart J 2006;27:2623–31.
3 f Card
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[84 P. Bobbert et al. / Journal o
12] Vallbracht KB, Schwimmbeck PL, Kuhl U, Rauch U, Seeberg B, Schultheiss
HP. Differential aspects of endothelial function of the coronary micro-
circulation considering myocardial virus persistence, endothelial
activation, and myocardial leukocyte inﬁltrates. Circulation 2005;111:
1784–91.
13] Weikert U, Kuhl U, Schultheiss HP, Rauch U. Platelet activation is increased in
patients with cardiomyopathy: myocardial inﬂammation and platelet reactiv-
ity. Platelets 2002;13:487–91.
14] Aretz HT, Billingham ME,  Edwards WD,  Factor SM,  Fallon JT, Fenoglio JJ, Olsen Jr
EG,  Schoen FJ. Myocarditis A histopathologic deﬁnition and classiﬁcation. Am
J  Cardiovasc Pathol 1987;1:3–14.
15] Noutsias M,  Rohde M,  Block A, Klippert K, Lettau O, Blunert K, Hummel M,  Kuhl
U,  Lehmkuhl H, Hetzer R, Rauch U, Poller W,  Pauschinger M, Schultheiss HP,
Volk HD, et al. Preampliﬁcation techniques for real-time RT-PCR analyses of
endomyocardial biopsies. BMC  Mol  Biol 2008;9:3.
16] Bobbert P, Scheibenbogen C, Jenke A, Kania G, Wilk S, Krohn S, Stehr J, Kuehl U,
Rauch U, Eriksson U, Schultheiss HP, Poller W,  Skurk C. Adiponectin expression
in patients with inﬂammatory cardiomyopathy indicates favourable outcome
and  inﬂammation control. Eur Heart J 2011;32:1134–47.
17] Noutsias M,  Seeberg B, Schultheiss HP, Kuhl U. Expression of cell adhesion
molecules in dilated cardiomyopathy: evidence for endothelial activation in
inﬂammatory cardiomyopathy. Circulation 1999;99:2124–31.
18] Rauch U, Schwippert B, Schultheiss HP, Tschoepe D. Platelet activation in dia-
betic microangiopathy. Platelets 1998;9:237–40.
19] Piorkowski M, Weikert U, Schwimmbeck PL, Martus P, Schultheiss HP,
Rauch U. ADP induced platelet degranulation in healthy individuals is
reduced by clopidogrel after pretreatment with atorvastatin. Thromb Haemost
2004;92:614–20.
20] Piorkowski M,  Priess J, Weikert U, Jaster M,  Schwimmbeck PL, Schultheiss HP,
Rauch U. Abciximab therapy is associated with increased platelet activation
and  decreased heparin dosage in patients with acute myocardial infarction.
Thromb Haemost 2005;94:422–6.
21] Piorkowski M,  Fischer S, Stellbaum C, Jaster M,  Martus P, Morguet
AJ,  Schultheiss HP, Rauch U. Treatment with ezetimibe plus low-dose
atorvastatin compared with higher-dose atorvastatin alone: is sufﬁcient
cholesterol-lowering enough to inhibit platelets. J Am Coll Cardiol 2007;49:
1035–42.
22] Homma  S, Thompson JL, Pullicino PM,  Levin B, Freudenberger RS, Teerlink JR,
Ammon SE, Graham S, Sacco RL, Mann DL, Mohr JP, Massie BM,  Labovitz AJ,
Anker SD, Lok DJ, et al. Warfarin and aspirin in patients with heart failure and
sinus rhythm. N Engl J Med  2012;366:1859–69.23] Massie BM,  Collins JF, Ammon  SE, Armstrong PW,  Cleland JG, Ezekowitz M,
Jafri SM,  Krol WF,  O’Connor CM,  Schulman KA, Teo K, Warren SR. Randomized
trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure:
the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial.
Circulation 2009;119:1616–24.
[iology 63 (2014) 379–384
24] Alberts VP, Bos MJ,  Koudstaal PJ, Hofman A, Witteman JC, Stricker BH, Breteler
MM.  Heart failure and the risk of stroke: the Rotterdam Study. Eur J Epidemiol
2010;25:807–12.
25] Witt BJ, Gami AS, Ballman KV, Brown Jr RD, Meverden RA, Jacobsen SJ, Roger
VL.  The incidence of ischemic stroke in chronic heart failure: a meta-analysis.
J  Card Fail 2007;13:489–96.
26] Albers GW,  Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and throm-
bolytic therapy for ischemic stroke: American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133,
630S-69S.
27] Jessup M,  Abraham WT,  Casey DE, Feldman AM,  Francis GS,  Ganiats TG,
Konstam MA,  Mancini DM,  Rahko PS, Silver MA,  Stevenson LW,  Yancy CW.  2009
focused update: ACCF/AHA Guidelines for the Diagnosis and Management of
Heart Failure in Adults: a report of the American College of Cardiology Founda-
tion/American Heart Association Task Force on Practice Guidelines: developed
in  collaboration with the International Society for Heart and Lung Transplan-
tation. Circulation 2009;119:1977–2016.
28] Jafri SM, Ozawa T, Mammen E, Levine TB, Johnson C, Goldstein S. Platelet func-
tion, thrombin and ﬁbrinolytic activity in patients with heart failure. Eur Heart
J  1993;14:205–12.
29] Mazzone M,  La SM,  Portale G, Ursella S, Forte P, Carbone L, Testa A, Pignataro G,
Covino M,  Gentiloni SN. Review of dilated cardiomyopathies. Dilated cardiomy-
opathies and altered prothrombotic state: a point of view of the literature.
Panminerva Med  2005;47:157–67.
30] Fischer D, Rossa S, Landmesser U, Spiekermann S, Engberding N, Hornig B,
Drexler H. Endothelial dysfunction in patients with chronic heart failure is
independently associated with increased incidence of hospitalization, cardiac
transplantation, or death. Eur Heart J 2005;26:65–9.
31] Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GY. Endothelial dys-
function and damage in congestive heart failure: relation of ﬂow-mediated
dilation to circulating endothelial cells, plasma indexes of endothelial damage,
and  brain natriuretic peptide. Circulation 2004;110:1794–8.
32] Kojima J, Miyazaki S, Fujiwara H, Kumada T, Kawai C. Recurrent left ventricular
mural thrombi in a patient with acute myocarditis. Heart Vessels 1988;4:120–2.
33] Kishimoto C, Ochiai H, Sasayama S. Intracardiac thrombus in murine
Coxsackievirus B3 myocarditis. Heart Vessels 1992;7:76–81.
34] Antoniak S, Boltzen U, Riad A, Kallwellis-Opara A, Rohde M,  Dorner A, Tschope
C,  Noutsias M,  Pauschinger M,  Schultheiss HP, Rauch U.  Viral myocarditis and
coagulopathy: increased tissue factor expression and plasma thrombogenicity.
J  Mol  Cell Cardiol 2008;45:118–26.
35] Boltzen U, Eisenreich A, Antoniak S, Weithaeuser A, Fechner H, Poller W,
Schultheiss HP, Mackman N, Rauch U. Alternatively spliced tissue factor and
full-length tissue factor protect cardiomyocytes against TNF-alpha-induced
apoptosis. J Mol  Cell Cardiol 2012;52:1056–65.
36] Rauch U. Tissue factor and cardiomyocytes. Thromb Res 2012;129
(Suppl. 2):S41–3.
